Seraxis
PrivateLast Round
Grant
May 13, 2025
Total Funding Raised
$59.02M
Company Overview
Seraxis is a biotechnology company that develops cell replacement therapies to provide a long-term cure for insulin-dependent diabetes by producing insulin to regulate glucose levels without requiring immune suppression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Seraxis Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Seraxis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 13, 2025 | ||||
| Grant | Jun 14, 2024 | ||||
| Grant | May 14, 2024 | ||||
| Series C Extension | Sep 21, 2023 | ||||
| Series C | Feb 9, 2021 | ||||
Grant | May 11, 2017 |
Seraxis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Frazier Healthcare Partners | Series C |
| ASAP Ventures | Series A |
| Frazier Life Sciences | Series C, Series C Extension |
| East West Capital Partners | Series A |
| JDRF | Series C, Series C Extension |
| Maryland Stem Cell Research Fund | Grant |
| Polaris Partners | Series C, Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 21, 2023
$10M round with Frazier Life Sciences and Polaris Partners.
Seraxis Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Seraxis's valuation, stock price, and market status.